Pipeline
We are advancing a diverse pipeline of precision medicines for the treatment of blood cancers and solid tumors.
Our programs consist of small molecule drug candidates that target cancer signaling pathways, where each program builds on our expertise in precision medicines.
Program
Development Approach
Research
Dose Escalation
Dose Optimization
Registration-Enabling
Regulatory Submission
Clinical Trial
Menin Inhibitor
Ziftomenib**
Monotherapy
Monotherapy
Monotherapy
Combinations with venetoclax/azacitidine, and cytarabine + daunorubicin (7+3)
Combinations with venetoclax/azacitidine, and cytarabine + daunorubicin (7+3)
Combinations with gilteritinib, FLAG-IDA, LDAC
Combinations with venetoclax/azacitidine, cytarabine + daunorubicin (7+3)
Ziftomenib
Ziftomenib is being investigated in up to 50% of AMLs, including NPM1-mutant AML and KMT2A-rearranged AML. It is also being investigated in combination with other cancer therapies.
**In Nov. 2024, Kura entered a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies.
Farnesyl Transferase Inhibitors
KO-2806
NEXT-GEN FTI
Monotherapy, combinations with cabozantinib and adagrasib
KO-2806
KO-2806 is an investigational potent next-generation FTI designed to potentially improve upon earlier FTI drug candidates. KO-2806 is not FDA-approved and safety and efficacy have not been established.
Farnesyl Transferase Inhibitors
Tipifarnib
Combination with alpelisib
Tipifarnib
Tipifarnib is an oral investigational FTI that is not FDA-approved. Safety and efficacy have not been established.
Next-Gen Menin Inhibitor
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.
FLAG-IDA: fludarabine, high-dose cytarabine (Ara-C), granulocyte-colony stimulating factor (G-CSF) and idarubicin; LDAC: Low-dose cytarabine
XOSPATA® (gilteritinib); PIQRAY® (alpelisib)
1 NDA accepted for filing with PDUFA date of November 30, 2025.
2 KOMET-017 program to advance directly to Registration-Enabling trials, leveraging data from Phase 1 combination trials.
3 Enrollment is complete.
ABOUT MENIN INHIBITORS
Most cancer drugs work by killing diseased cells faster than they kill healthy tissue. But what if you didn’t have to kill the cancer cell? What if you could convince it to differentiate? That’s the mechanism underlying an emerging class of targeted therapies called menin inhibitors.
Our menin inhibitor, ziftomenib, inhibits the interaction of two proteins, menin and KMT2A/MLL, that, when fused together, are responsible for survival and proliferation of certain kinds of leukemia cells. When this process is inhibited, cancerous juvenile cells are thought to mature into white blood cells.
ABOUT FARNESYL TRANSFERASE INHIBITORS
Imagine if a single key had the potential to unlock multiple targeted treatment paths for a range of difficult cancers. A class of medicines known as farnesyl transferase inhibitors may hold that ability.
Farnesyltransferase is an enzyme that plays a key regulatory role in cellular pathways that drive resistance to a range of targeted therapies in different types of tumors. By inhibiting the enzyme’s function, we believe we can reshape combination treatment options for many cancers.
Our investigational drug tipifarnib is a farnesyl transferase inhibitor, or FTI, that is being studied in a genetically defined subset of head and neck squamous cell carcinoma (HNSCC) — specifically in tumors that express a mutation in the HRAS proto-oncogene. KO-2806 is an investigational potent next-generation inhibitor of farnesyl transferase designed to potentially improve upon earlier FTI drug candidates.